After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours.
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of BridgeBio Pharma Inc is $7.33B. A total of 2.63 million shares were traded on the day, compared to an average of 2.96M shares.
In the most recent transaction, Kumar Neil sold 75,000 shares of BBIO for 33.40 per share on May 20 ’25. After the transaction, the Chief Executive Officer now owns 4,798,447 company shares. In a previous transaction on May 19 ’25, Kumar Neil sold 26,156 shares at 33.33 per share. BBIO shares that Chief Executive Officer owns now total 217,404.
Among the insiders who bought shares, NEIL KUMAR acquired of 26,156 shares on May 19 ’25 at a per-share price of $33.84. In another insider transaction, KKR Genetic Disorder L.P. sold 6,000,000 shares at $34.20 per share on May 12 ’25. Company shares held by the 10% Owner now total 13,260,971.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, BBIO has a high of $39.54 and a low of $21.62.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.72.
